Estimation of Clinically Important Change for Visual Analog Scales Measuring Chronic Temporomandibular Disorder Pain

Aims: To estimate the clinically important change (CIC) on a 100-mm visual analog scale for pain intensity (VAS-PI) by relating it to the patient’s global impression of change (PGIC) in patients with chronic temporomandibular disorder (TMD) pain and to assess the dependency of the CIC on their baseline pain scores. Methods: Data from a prospective cohort study with 588 patients with chronic TMD pain were analyzed. The CIC was estimated over a 3-month period, and receiver operating characteristic meth-ods were used to assess the optimal cut-off point. The PGIC cate-gory of “much improved” served as an external criterion. Dependency of absolute and percent change on baseline VAS-PI scores was determined by linear regression analysis. Results: A VAS-PI change score of –19.5 mm and a percent change score of –37.9% were best associated with the concept of CIC. Since patients with high baseline pain required greater absolute reductions in pain to reach a clinically important improvement, percent change scores performed better in classifying improved patients. Conclusion: Providing a standard definition of the CIC adds to the interpretability of study results, ie, the estimates will aid in understanding individual patient outcomes.

chronic pain;minimal clinically important change;temporomandibular disorder

1. Okeson JP (ed). Orofacial Pain: Guidelines for Assessment, Diagnosis, and Management. Chicago: Quintessence, 1996:113–184.

2. Rantala MAI, Ahlberg J, Suvinen TI, Savolainen A, Könönen M. Symptoms, signs, and clinical diagnoses according to the research diagnostic criteria for temporomandibular disorders among Finnish multiprofessional media personnel. J Orofac Pain 2003;17:311–316.

3. Kuttila M, Kuttila S, Bell YL, Alanen P. Association between TMD treatment need, sick leaves, and use of health care services for adults. J Orofac Pain 1997; 11:242–248.

4. Macfarlane TV, Blinkhorn AS, Davies RM, Kincey J, Worthington HV. Orofacial pain in the community: Prevalence and associated impact. Community Dent Oral Epidemiol 2002;30:52–60.

5. Voog U, Alstergren P, Leibur E, Kallikorm R, Kopp S. Impact of temporomandibular joint pain on activities of daily living in patients with rheumatoid arthritis. Acta Odontol Scand 2003;61:278–282.

6. Murray H, Locker D, Mock D, Tenenbaum HC. Pain and the quality of life in patients referred to a craniofacial pain unit. J Orofac Pain 1996;10:316–323.

7. List T, Helkimo M. A scale for measuring the activities of daily living (ADL) of patients with craniomandibular disorders. Swed Dent J 1995;19:33–40.

8. Jaeschke R, Singer J, Guyatt GH. Measurement of health status: Ascertaining the minimal clinically important difference. Control Clin Trials 1989;10:407–415.

9. Redelmeier DA, Lorig K. Assessing the clinical importance of symptomatic improvements: An illustration in rheumatology. Arch Intern Med 1993;153:1337–1342.

10. Fortin PR, Stuki G, Katz JN. Measuring relevant change: An emerging challenge in rheumatologic clinical trials. Arthritis Rheum 1995;38:1027–1030.

11. Deyo RA, Diehr P, Patrick DL. Reproducibility and responsiveness of health status measures. Statistics and strategies for evaluation. Control Clin Trials 1991;12: 142S–158S.

12. Tubach F, Ravaud P, Beaton D, et al. Minimal clinically important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic disor-ders. J Rheumatol 2007;34:1188–1193.

13. Bird SB, Dickson EW. Clinically significant changes in pain along the visual analog scale. Ann Emerg Med 2001;38:639–643.

14. Todd KH. Patient-oriented outcome measures: The promise of definition. Ann Emerg Med 2001;38:672–674.

15. Dworkin SF, LeResche L. Research diagnostic criteria for temporomandibular disorders: Review, criteria, examinations and specifications, critique. J Craniomandib Disord 1992;6:301–355.

16. Conti PC, dos Santos CN, Kogawa EM, de Castro Ferreira Conti AC, de Araujo Cdos R. The treatment of painful temporomandibular joint clicking with oral splints: A ran-domized clinical trial. J Am Dent Assoc 2006;137: 1108–1114.

17. Ta LE, Dionne RA. Treatment of painful temporo-mandibular joints with a cyclooxygenase-2 inhibitor: A randomized placebo-controlled comparison of celecoxib to naproxen. Pain 2004;111:13–21.

18. Minakuchi H, Kuboki T, Matsuka Y, Maekawa K, Yatani H, Yamashita A. Randomized controlled evaluation of non-surgical treatments for temporomandibular joint anterior disk displacement without reduction. J Dent Res 2001;80:924–928.

19. Price DD, McGrath PA, Rafii A. The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain 1983;17:45–56

20. Seymour RA, Simpson JM, Charlton JE, Phillips ME. An evaluation of length and end-phrase of visual analogue scales in dental pain. Pain 1985;21:177–185.

21. Ferraz MB, Quaresma MR, Aquino LR, Atra E, Tugwell P, Goldsmith CH. Reliability of pain scales in the assessment of literate and illiterate patients with rheumatoid arthritis. J Rheumatol 1990;17:1022–1024.

22. Breivik EK, Bjornsson GA, Skovlund E. A comparison of pain rating scales by sampling from clinical trial data. Clin J Pain 2000;16:22–28.

23. Ehrich EW, Davies GM, Watson DJ, Bolognese JA, Seidenberg BC, Bellamy N. Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessment in patients with osteoarthritis. J Rheumatol 2000;27:2635–2641.

24. Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE Jr. Determining minimally important changes in generic and disease specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000;43:1478–1487.

25. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001;94:149–158.

26. Angst F, Aeschlimann A, Michel BA, Stuki G. Minimal clinically important rehabilitation effects in patients with osteoarthritis of the lower extremities. J Rheumatol 2002; 29:131–138.

27. Liang HL. Evaluating measurement responsiveness. J Rheumatol 1995;22:1191–1192.

28. Hauley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983;148:839–843.

29. Swets JA. Measuring the accuracy of diagnostic systems. Science 1988;240:1285–1293.

30. Salaffi F, Stancati A, Silvestri CA, Ciapetti A, Grassi A. Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. Eur J Pain 2004;8:283–291.

31. Goldsmith CH, Boers M, Bombardier C, Tugwell P. Criteria for clinically important changes in outcomes: Development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. OMERACT Committee. J Rheumatol 1993;20:561–565.

32. Lee JS, Hobden E, Stiell IG, Wells GA. Clinically important change in the visual analog scale after adequate pain control. Acad Emerg Med 2003;10:1128–1130.

33. Giraudeau B, Rozenberg S, Valat JP. Assessment of the clinically relevant change in pain for patients with sciatica. Ann Rheum Dis 2004;63:1180–1181.

34. Kvien TK, Dougados M, Mowinckel P, Skomsvoll JF, Mikkelsen K. Values for Minimal Clinically Important Improvement (MCII) in patients with Ankylosing Spondylitis. Poster presented at the Annual Scientific Meeting of the American College of Rheumatology, San Antonio, Texas, 2004.

35. Felson DT, Anderson JJ. A review of evidence on the discriminant validity of outcome measures in rheumatoid arthritis. J Rheumatol 2001;28:422–426

36. Wolfe F, Michaud K, Strand V. Expanding the definition of clinical differences: From minimally clinically important differences to really important differences. Analyses in 8931 patients with rheumatoid arthritis. J Rheumatol 2005;32:583–589.

37. Rethelyi JM, Berghammer R, Kopp MS. Comorbidity of pain-associated disability and depressive symptoms in connection with sociodemographic variables: Results from a cross-sectional epidemiological survey in Hungary. Pain 2001;93:115–121.

38. Wassell RW, Moufti AM, Meechan JG, Steen IN, Steele JG. A method for clinically defining “improvers” in chronic pain patients. J Orofac Pain 2008;22:30–40.

39. Just N, Ciccone DS, Bandilla EB, Wu W. Global impressions versus validated measures of treatment effectiveness in patients with chronic nonmalignant pain. Rehabil Psychol 1999;44:194–207.

40. Buchbinder R, Bombardier C, Yeung M, Tugwell P. Which outcome measures should be used in rheumatoid arthritis clinical trials? Clinical and quality-of-life measures’ respon-siveness to treatment in a randomized controlled trial. Arthritis Rheum 1995;38:1568–1580.

41. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994;47:81–87.

42. Beurskens AJ, de Vet HC, Koke AJ. Responsiveness of functional status in low back pain: A comparison of different instruments. Pain 1996;65:71–76.